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Men newly diagnosed with localised prostate cancer 
are facing difficult decisions regarding their 
treatment. They need to choose from a range of 
treatment options (e.g., surgery, external beam 
radiotherapy, brachytherapy, or active surveillance), 
which have equivalent survival outcomes but differ in 
the risk of adverse events1,2. 
In the process of shared decision making, decision 
aids (web-based tools) provide information about 
treatment options and associated risks of side effects, 
and help patients get to know their values and 
preferences3. Today, there are many patient decision 
aids available for prostate cancer patients, and 
according to a large Cochrane review, they seem to be 
effective4. However, what is their quality? And to 
which extent do decision aids pay attention to 
communication features?
Large-scale systematic review
To answer these questions, a group of Dutch (health 
communication) scholars recently performed a 
large-scale systematic review to assess the quality 
and use of communication in currently available 
decision aids for patients with localised prostate 
cancer. They systematically searched through 
academic databases such as EMBASE or MEDLINE to 
collect decision aids that were, for instance, part of 
interventions in randomised controlled trials. In 
addition, they performed a thorough search through 
Google, since patients are more likely to find their 
information and decision aids in this environment5. 
The quality and use of communication in PCa decision aids 
Results from a large-scale systematic review assessing 19 tools for localised PCa patients
Eventually, they identified 19 international decision 
aids, of which 11 originated from North America and 
eight from Europe. The majority of the aids (12) were 
web-based tools, and the year of publication ranged 
from 2007-2018. 
IPDAS checklist
The authors first assessed the quality of the tools by 
using the validated International Patient Decision Aids 
Standards (IPDAS) checklist6, which covers a variety of 
quality dimensions, ranging from evidence-based 
information about treatment options and outcome 
probabilities to decision guidance and development 
process. The authors found that the quality varied 
greatly across the decision aids, with many failing to 
comply with all components of the IPDAS criteria 
(mean IPDAS score = 59%, range = 36%-84%). This is 
also shown in Figure 1A, in which there is large 
variability for many IPDAS dimensions. Many aids did 
not adhere to good practice guidance on the 
presentation of outcome probabilities associated with 
treatment options, and lacked substantial information 
regarding the development process and readability 
levels of the aids.
Communicative Aspects checklist
After the quality assessment, the authors further 
reviewed the decision aids regarding their use of 
communication for which they developed the 
Communicative Aspects (CA) checklist7,8. This 
tumour-independent checklist consists of 76 items 
divided into seven aspects: Information Presentation 
(e.g., how risks and uncertainties were 
communicated), Personalisation (e.g., how 
treatment information was tailored to patient 
characteristics), Interaction (e.g., how patients’ 
personal values and preferences were clarified), 
Information Control (e.g., how patients had control 
over access to and amount of information), 
Accessibility (e.g., whether the tool was easily 
accessible), Suitability (e.g., how suitable and 
understandable the content was) and finally Source 
of Information (e.g., whether and how the source of 
treatment information was given). 
Results
The authors observed substantial variations in use of 
communication in decision aids (Figure 1B), with a 
mean CA score of 51% (range 32%-64%). Most 
importantly, few aids used visuals to communicate 
outcome probabilities, and none of them were 
personalised in terms of communicating the likelihood 
of experiencing treatment side effects. Furthermore, 
only a minority of the aids used interactive exercises to 
elicit patients’ values and preferences, and most tools 
had biased cross tables to compare the pros and cons 
of treatment options. The authors also found some 
issues with the suitability and accessibility of 
information in the aids that may hinder the uptake of 
decision aids in daily clinical practice.
Conclusion
What we learn from this? According to the authors, 
this review demonstrates the variability among 
currently available decision aids for localised 
prostate cancer treatment, and shows that both their 
quality and use of communication can be improved. 
The authors recommend urologists who are using or 
developing decision aids to focus on personalisation 
techniques, such as communicating individualised 
risks of treatment side effects or tailoring the 
amount of treatment information to patient 
characteristics and preferences. Other possible 
improvements are the inclusion of interaction 
exercises for clarifying patients’ preferences and 
values, and using both text and visualisations for 
communicating statistical information. These 
suggestions are also relevant for clinicians outside of 
prostate cancer who are facing similar complex and 




1.  Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes 
after monitoring, surgery, or radiotherapy for localized 
prostate cancer. N Engl J Med. 2016;375(15):1415-1424. 
doi:10.1056/NEJMoa1606220
2.  Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported 
outcomes after monitoring, surgery, or radiotherapy for 
prostate cancer. J Urol. 2017;375(15):1425-1437. 
doi:10.1016/j.juro.2017.02.004
3.  Elwyn G, Durand MA, Song J, et al. A three-talk model for 
shared decision making: Multistage consultation process. 
Bmj. 2017;359:j4891. doi:10.1136/bmj.j4891
4.  Stacey D, Légaré F, Lewis K, et al. Decision aids for people 
facing health treatment or screening decisions. Cochrane 
Database Syst Rev. 2017;4:CD001431. doi:10.1002/14651858.
CD001431.pub5
5.  van Eenbergen MCHJ, Vromans RD, Boll D, et al. Changes 
in internet use and wishes of cancer survivors : A 
comparison between 2005 and 2017. Cancer. 
2019;126(2):408-415. doi:10.1002/cncr.32524
6.  Elwyn G, O’Connor AM, Bennett C, et al. Assessing the 
quality of decision support technologies using the 
International Patient Decision Aid Standards instrument 
(IPDASi). PLoS One. 2009;4(3):e4705. doi:10.1371/journal.
pone.0004705
7.  Vromans RD, van Eenbergen MC, Pauws SC, et al. 
Communicative aspects of decision aids for localized 
prostate cancer treatment – A systematic review. Urol 
Oncol Semin Orig Investig. 2019;37(7):409-429. 
doi:10.1016/j.urolonc.2019.04.005
8.  Vromans R, Tenfelde K, Pauws S, et al. Assessing the 
quality and communicative aspects of patient decision 
aids for early -stage breast cancer treatment: A systematic 
review. Breast Cancer Res Treat. 2019;178(1):1-15. 
doi:10.1007/s10549-019-05351-4
Source: Communicative aspects of decision aids for 
localized prostate cancer treatment: A systematic 
review. Vromans RD, van Eenbergen MC, Pauws SC, 
Geleijnse G, van der Poel HG, van de Poll-Franse LV, 
Krahmer EJ. Urol Oncol Semin Orig Investig. 2019 
Apr;37(7):409-429. https://doi.org/10.1016/j.
urolonc.2019.04.005
Figure 1: Quality (A) and use of communication aspects (B) of the 19 international decision aids for prostate cancer treatment. 
Within each IPDAS dimension or CA aspect, each dot represents one decision aid
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